COVID-19 Staff Shakeup: Woodcock Moves to Commissioner's Office As Marks Drops Out Of 'Warp'

CBER Director Marks will no longer have to recuse himself from COVID-19 product reviews, a move seen as resoundingly positive by former senior FDA leaders. CDER Director Woodcock will now be free to focus solely on COVID-19 and bring her unique depth of agency experience to the Trump Administration's effort to speed development of vaccines, therapeutics and diagnostics for coronavirus.

Restructuring the company to better face the present reality
Key staffing changes are being made at FDA to tackle COVID-19 • Source: Shutterstock

The latest staff shakeup at the US Food and Drug Administration to fight COVID-19 will likely make better use of senior career staffers in tackling the pandemic than a plan laid out just a week earlier, experts say.

Center for Drug Evaluation and Research Director Janet Woodcock is moving temporarily to the commissioner’s office so she can be solely focused on Operation Warp Speed, the US effort to facilitate the development, manufacturing and distribution of COVID-19 vaccines, therapeutics and diagnostics

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from US FDA

More from Agency Leadership